News >

EU Approves Pembrolizumab for Hodgkin Lymphoma

Jason M. Broderick @jasoncology
Published: Friday, May 05, 2017

Pier Luigi Zinzani, MD, PhD

Pier Luigi Zinzani, MD, PhD

The European Commission (EC) has approved pembrolizumab (Keytruda) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have progressed following autologous stem cell transplant (ASCT) and brentuximab vedotin (Adcetris), or who are transplant-ineligible and have failed brentuximab vedotin.

“Today’s approval brings an important new treatment option to patients in Europe with classical Hodgkin lymphoma who have not responded to existing therapies,” Roger Dansey, MD, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories, the manufacturer of pembrolizumab, said in a statement. “This milestone underscores our commitment to evaluating Keytruda in diseases with unmet need facing the hematology community.”

References

  1. Chen RW, Zinzani PL, Fanale MA, et al. Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J Clin Oncol 34, 2016 (suppl; abstr 7555).
  2. Armand P, Shipp MA, Ribrag V, et al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Presented at: 57th American Society of Hematology Annual Meeting; Orlando, Florida; December 5-8, 2015. Abstract 680.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x